EAM Investors’s Axsome Therapeutics AXSM Stock Holding History

EAM Investors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.4M	Sell	26,152 -414	-2%	-$89.8K	0.57%	51
2026 Q1	$4.49M	Buy	+26,566	New	+$4.59M	0.52%	70
2025 Q2	–	Sell	-42,222	Closed	-$4.92M	–	241
2025 Q1	$4.92M	Buy	+42,222	New	+$4.81M	0.85%	10
2023 Q3	–	Sell	-18,102	Closed	-$1.3M	–	287
2023 Q2	$1.3M	Buy	+18,102	New	+$1.34M	0.24%	191
2023 Q1	–	Sell	-14,458	Closed	-$1.12M	–	261
2022 Q4	$1.12M	Sell	14,458 -37,634	-72%	-$2.25M	0.23%	207
2022 Q3	$2.32M	Buy	52,092 +932	+2%	+$46.6K	0.51%	74
2022 Q2	$1.96M	Buy	+51,160	New	+$1.62M	0.48%	72
2020 Q3	–	Sell	-29,293	Closed	-$2.41M	–	282
2020 Q2	$2.41M	Sell	29,293 -45,942	-61%	-$3.54M	0.53%	51
2020 Q1	$4.43M	Buy	75,235 +3,679	+5%	+$300K	1.37%	1
2019 Q4	$7.4M	Sell	71,556 -58,028	-45%	-$2.34M	1.63%	1
2019 Q3	$2.62M	Sell	129,584 -18,887	-13%	-$485K	0.69%	31
2019 Q2	$3.82M	Sell	148,471 -78,770	-35%	-$1.58M	0.94%	5
2019 Q1	$3.23M	Buy	+227,241	New	+$2.11M	0.79%	15

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EAM Investors's AXSM Position: Q2 2026 in Review

EAM Investors reduced its Axsome Therapeutics (AXSM) stake by 1.6% in Q2 2026, selling an estimated $89.8K and leaving 26,152 shares worth $6.4M. The position accounts for 0.57% of the portfolio, ranked #51.

EAM Investors first reported a position in AXSM in Q1 2019 and has held it in 13 quarters since. The position peaked at $7.4M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

EAM Investors held 26,152 shares of Axsome Therapeutics worth $6.4M as of Q2 2026.
EAM Investors sold 414 Axsome Therapeutics shares in Q2 2026, an estimated $89.8K.
Axsome Therapeutics made up 0.57% of EAM Investors's portfolio in Q2 2026, its #51 holding.
EAM Investors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 13 quarters since.
EAM Investors's Axsome Therapeutics position peaked at $7.4M in Q4 2019.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.